Kanan Alshammari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kanan Alshammari has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Mohammad Alkaiyat
Department of Oncology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs
3 shared publications Husam Ardah
King Abdullah International Medical Research Center, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia
2 shared publicationsHusam Shehata
Department of Medical Oncology, King Abdulaziz Medical City, Ministry of National Guard for Health Affairs
2 shared publicationsAaron R. Hansen
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Ontario
1 shared publication- Abdulaziz Alosaimi
King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Riyadh 11481, Saudi Arabia
1 shared publication Abdulaziz Alsuaib
College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (7) , e2500254
Exploring Factors Affecting Participation in Oncology Clinical Trials in Saudi Arabia: Insights Into Willingness and Barriers
PURPOSE: To assess willingness of patients with cancer to participate in observational studies (OBS) and clinical trials (CT) and to examine the factors influencing their decision to join CT. METHODS: A cross-sectional study using a systematic sampling strategy was conducted from December 2023 to June 2024. Data were collected directly from patients and their medical charts. Logistic regression was performed to identify significant predictors of patients' willingness to participate in CT. RESULTS: A total of 367 patients participated, 58.9% were females, and 59.8% had stage IV disease. Most participants (81%) had a performance status (PS) of 0-1, with only 1.9% having prior experience with a CT and 9% with OBS. Willingness to join OBS was higher than willingness to join CT (64% v 31.6%, P < .001). Key barriers included fear of side effects (61.6%), lack of information (46.3%), and concerns about the investigational product (41.6%). Motivators were having their treating physician as the principal investigator (42.5%) and prior human testing of the product (40.6%). Patients who underwent surgery or believed that their physical or psychological condition is unsuitable for trials were less likely to participate ( P < .05, odds ratio [OR], 0.30, 0.38, 0.37, respectively). Patients with a friend or relative who had joined a trial were more willing to participate ( P < .05, OR, 3.48). CONCLUSION: The results highlight a low level of willingness to participate in CT. Some barriers could be avoided during the study design phase. Discrepancies between patients' self-assessed PS and physicians' evaluations may lower the enrollment rates. Encouraging patients who have participated in CTs to share their experiences with the family and friends could significantly improve the community's willingness to join CT.
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (7) , e2500254
Open AccessExploring Factors Affecting Participation in Oncology Clinical Trials in Saudi Arabia: Insights Into Willingness and Barriers
PURPOSE: To assess willingness of patients with cancer to participate in observational studies (OBS) and clinical trials (CT) and to examine the factors influencing their decision to join CT. METHODS: A cross-sectional study using a systematic sampling strategy was conducted from December 2023 to June 2024. Data were collected directly from patients and their medical charts. Logistic regression was performed to identify significant predictors of patients' willingness to participate in CT. RESULTS: A total of 367 patients participated, 58.9% were females, and 59.8% had stage IV disease. Most participants (81%) had a performance status (PS) of 0-1, with only 1.9% having prior experience with a CT and 9% with OBS. Willingness to join OBS was higher than willingness to join CT (64% v 31.6%, P < .001). Key barriers included fear of side effects (61.6%), lack of information (46.3%), and concerns about the investigational product (41.6%). Motivators were having their treating physician as the principal investigator (42.5%) and prior human testing of the product (40.6%). Patients who underwent surgery or believed that their physical or psychological condition is unsuitable for trials were less likely to participate ( P < .05, odds ratio [OR], 0.30, 0.38, 0.37, respectively). Patients with a friend or relative who had joined a trial were more willing to participate ( P < .05, OR, 3.48). CONCLUSION: The results highlight a low level of willingness to participate in CT. Some barriers could be avoided during the study design phase. Discrepancies between patients' self-assessed PS and physicians' evaluations may lower the enrollment rates. Encouraging patients who have participated in CTs to share their experiences with the family and friends could significantly improve the community's willingness to join CT.
- Open Access
- 29 June 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1712037
Survival outcomes and prognostic factors in de novo advanced biliary tract cancer: insights from a Saudi multicenter cohort
Purpose: Advanced biliary tract cancer (BTC) carries a poor prognosis, with limited regional data available. This study evaluated outcomes, treatment patterns, and prognostic factors in a multicenter cohort of patients with de novo advanced BTC. Methods: A retrospective cohort of 271 patients with de novo advanced biliary tract cancer diagnosed at five tertiary centers in Saudi Arabia (2016–2023) was analyzed. Clinical, pathological, treatment, and molecular data were extracted from electronic health records. Overall survival was estimated using the Kaplan–Meier analysis, and prognostic factors were assessed through multivariable Cox regression. Results: Systemic therapy was administered to 211 patients (77.9%). Among the entire cohort, 92 patients (33.9%) received second-line therapy, 25 (9.2%) received third-line therapy, and 8 (3.0%) received fourth-line therapy. Median overall survival (OS) was 9.5 months (95% CI, 8.4–10.6). On multivariable analysis, inferior OS was independently associated with poor ECOG performance status (PS 4: HR 4.08, P = 0.031), age 15–39 years (HR 4.44, P < 0.001), extrahepatic cholangiocarcinoma (HR 1.91, P = 0.017), cirrhosis (HR 3.13, P = 0.004), and elevated CEA (HR 1.92, P = 0.003). Patients with disease control had a 71% lower hazard of death (HR 0.29, 95% CI 0.18–0.47) and longer median OS (16.0 vs 7.7 months). Conclusions: Advanced BTC in Saudi Arabia demonstrates poor outcomes, with survival strongly influenced by performance status, age, tumor site, cirrhosis, and biomarkers. Treatment exposure was limited, with only one-third receiving second-line therapy, highlighting the urgent need for expanded access to immunotherapy and molecular profiling.
- 29 June 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1712037
Open AccessSurvival outcomes and prognostic factors in de novo advanced biliary tract cancer: insights from a Saudi multicenter cohort
Purpose: Advanced biliary tract cancer (BTC) carries a poor prognosis, with limited regional data available. This study evaluated outcomes, treatment patterns, and prognostic factors in a multicenter cohort of patients with de novo advanced BTC. Methods: A retrospective cohort of 271 patients with de novo advanced biliary tract cancer diagnosed at five tertiary centers in Saudi Arabia (2016–2023) was analyzed. Clinical, pathological, treatment, and molecular data were extracted from electronic health records. Overall survival was estimated using the Kaplan–Meier analysis, and prognostic factors were assessed through multivariable Cox regression. Results: Systemic therapy was administered to 211 patients (77.9%). Among the entire cohort, 92 patients (33.9%) received second-line therapy, 25 (9.2%) received third-line therapy, and 8 (3.0%) received fourth-line therapy. Median overall survival (OS) was 9.5 months (95% CI, 8.4–10.6). On multivariable analysis, inferior OS was independently associated with poor ECOG performance status (PS 4: HR 4.08, P = 0.031), age 15–39 years (HR 4.44, P < 0.001), extrahepatic cholangiocarcinoma (HR 1.91, P = 0.017), cirrhosis (HR 3.13, P = 0.004), and elevated CEA (HR 1.92, P = 0.003). Patients with disease control had a 71% lower hazard of death (HR 0.29, 95% CI 0.18–0.47) and longer median OS (16.0 vs 7.7 months). Conclusions: Advanced BTC in Saudi Arabia demonstrates poor outcomes, with survival strongly influenced by performance status, age, tumor site, cirrhosis, and biomarkers. Treatment exposure was limited, with only one-third receiving second-line therapy, highlighting the urgent need for expanded access to immunotherapy and molecular profiling.
- Open Access
- 12 June 2026
- Published by Elsevier in Journal of Cancer Policy
- Vol. 49, 100762
Reducing the burden through early detection: Health-economic impact of gastrointestinal cancers in Saudi Arabia
- 12 June 2026
- Published by Elsevier in Journal of Cancer Policy
- Vol. 49, 100762
Open AccessReducing the burden through early detection: Health-economic impact of gastrointestinal cancers in Saudi Arabia
- Open Access
- 5 February 2026
- Published by Society of Gastrointestinal Intervention in International Journal of Gastrointestinal Intervention
- Vol. 15 (4) , 194-201
Yttrium-90 radioembolization in the management of intrahepatic cholangiocarcinoma: Effectiveness and safety outcomes from a multicenter study
- 5 February 2026
- Published by Society of Gastrointestinal Intervention in International Journal of Gastrointestinal Intervention
- Vol. 15 (4) , 194-201
Open AccessYttrium-90 radioembolization in the management of intrahepatic cholangiocarcinoma: Effectiveness and safety outcomes from a multicenter study
- Open Access
- 1 July 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 1623-1632
Survival Outcomes and Prognostic Factors of Systemic Therapy for Advanced Hepatocellular Carcinoma: A Multidisciplinary Clinic Experience from Saudi Arabia
To investigate survival outcomes and prognostic factors of systemic therapies in advanced hepatocellular carcinoma (HCC) within Saudi Arabia, addressing the limited regional data. A retrospective review of 670 HCC patients was utilized. 130 patients with advanced HCC who received first-line systemic therapy were identified, and data on demographics, tumor characteristics, treatment regimens, laboratory findings, and survival outcomes were collected. Treatment response and survival outcomes were evaluated using RECIST criteria and the Kaplan-Meier method, respectively. Our population's mean age was 70.4, majority being males. Sorafenib was the most frequently used, then nivolumab and the atezolizumab-bevacizumab (Atezo+Bev) combination. Median overall survival (OS) varied by treatment: patients receiving Atezo+Bev showed the longest OS, followed by nivolumab and sorafenib. No statistically significant difference was observed in survival. Despite the small sample size, this trend suggests a potential OS benefit with Atezo+Bev, particularly in patients with advanced hepatic dysfunction. Furthermore, 39.1% of patients had elevated alpha-fetoprotein (AFP) levels and 26.8% had sarcopenia. Multivariate analysis highlighted the elevated neutrophil-to-lymphocyte ratio (NLR) as a significant predictor of worse survival, reinforcing its relevance as a prognostic marker in HCC. Although sarcopenia demonstrated an improved survival trend, it was not statistically significant. Adverse events were consistent, with elevated AST, anorexia, and fatigue frequently observed. This study illustrated Atezo+Bev's potential in improving OS in advanced HCC, with an elevated NLR identified as a key marker for poor prognosis. These findings support the need for prospective studies to confirm and expand regional insights into the management of HCC.
- 1 July 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 1623-1632
Open AccessSurvival Outcomes and Prognostic Factors of Systemic Therapy for Advanced Hepatocellular Carcinoma: A Multidisciplinary Clinic Experience from Saudi Arabia
To investigate survival outcomes and prognostic factors of systemic therapies in advanced hepatocellular carcinoma (HCC) within Saudi Arabia, addressing the limited regional data. A retrospective review of 670 HCC patients was utilized. 130 patients with advanced HCC who received first-line systemic therapy were identified, and data on demographics, tumor characteristics, treatment regimens, laboratory findings, and survival outcomes were collected. Treatment response and survival outcomes were evaluated using RECIST criteria and the Kaplan-Meier method, respectively. Our population's mean age was 70.4, majority being males. Sorafenib was the most frequently used, then nivolumab and the atezolizumab-bevacizumab (Atezo+Bev) combination. Median overall survival (OS) varied by treatment: patients receiving Atezo+Bev showed the longest OS, followed by nivolumab and sorafenib. No statistically significant difference was observed in survival. Despite the small sample size, this trend suggests a potential OS benefit with Atezo+Bev, particularly in patients with advanced hepatic dysfunction. Furthermore, 39.1% of patients had elevated alpha-fetoprotein (AFP) levels and 26.8% had sarcopenia. Multivariate analysis highlighted the elevated neutrophil-to-lymphocyte ratio (NLR) as a significant predictor of worse survival, reinforcing its relevance as a prognostic marker in HCC. Although sarcopenia demonstrated an improved survival trend, it was not statistically significant. Adverse events were consistent, with elevated AST, anorexia, and fatigue frequently observed. This study illustrated Atezo+Bev's potential in improving OS in advanced HCC, with an elevated NLR identified as a key marker for poor prognosis. These findings support the need for prospective studies to confirm and expand regional insights into the management of HCC.
- Open Access
- 1 January 2024
- Published by SAGE Publications in Clinical Medicine Insights: Oncology
- Vol. 18
Cardiac Morbidity and Mortality in Patients with Sarcoma: A Population-Based Study
Background: Soft tissue sarcoma (STS) is a rare malignancy that affects soft tissues. It encompasses various subtypes and requires different treatment strategies. Doxorubicin is a commonly used anthracycline in the management of localized and metastatic STS. However, high doses of doxorubicin are associated with cardiotoxicity, which can significantly impact patients’ long-term outcomes. This study aimed to evaluate doxorubicin’s effect on cardiac function in patients with sarcoma and to correlate the frequency of cardiotoxicity with potential risk factors. Methods: A retrospective analysis was conducted on patients with sarcoma who were treated with doxorubicin between 2016 and 2022 at King Abdulaziz Medical City in Saudi Arabia. Patient demographic information, comorbidities, cardiac measurements, laboratory values, systemic therapy, and treatment outcomes were collected from electronic medical records. A statistical analysis was performed to assess the association between cardiotoxicity and various factors. Results: A total of 133 patients were included in the study, with a median age of 30 years. Cardiotoxicity was observed in 9% of the patients. Female patients had a significantly higher risk of developing cardiotoxicity. Patients with a higher Eastern Cooperative Oncology Group (ECOG) performance status and lower troponin I levels also had an increased risk of cardiotoxicity. However, there was no significant association between cardiotoxicity and the number of chemotherapy cycles, total cumulative dose of doxorubicin, or history of radiation. Furthermore, patients with cardiotoxicity had a higher risk of mortality. The overall survival of the patients was 18 months. Conclusion: Doxorubicin-associated cardiotoxicity is a concern for patients with sarcoma. Female patients and patients with a higher ECOG performance status are at an increased risk of developing cardiotoxicity. Careful monitoring and risk assessment are crucial for mitigating the adverse effects of doxorubicin treatment in patients with sarcoma. Future studies are warranted to validate these findings and explore preventive strategies for doxorubicin-induced cardiotoxicity in patients with sarcoma.
- 1 January 2024
- Published by SAGE Publications in Clinical Medicine Insights: Oncology
- Vol. 18
Open AccessCardiac Morbidity and Mortality in Patients with Sarcoma: A Population-Based Study
Background: Soft tissue sarcoma (STS) is a rare malignancy that affects soft tissues. It encompasses various subtypes and requires different treatment strategies. Doxorubicin is a commonly used anthracycline in the management of localized and metastatic STS. However, high doses of doxorubicin are associated with cardiotoxicity, which can significantly impact patients’ long-term outcomes. This study aimed to evaluate doxorubicin’s effect on cardiac function in patients with sarcoma and to correlate the frequency of cardiotoxicity with potential risk factors. Methods: A retrospective analysis was conducted on patients with sarcoma who were treated with doxorubicin between 2016 and 2022 at King Abdulaziz Medical City in Saudi Arabia. Patient demographic information, comorbidities, cardiac measurements, laboratory values, systemic therapy, and treatment outcomes were collected from electronic medical records. A statistical analysis was performed to assess the association between cardiotoxicity and various factors. Results: A total of 133 patients were included in the study, with a median age of 30 years. Cardiotoxicity was observed in 9% of the patients. Female patients had a significantly higher risk of developing cardiotoxicity. Patients with a higher Eastern Cooperative Oncology Group (ECOG) performance status and lower troponin I levels also had an increased risk of cardiotoxicity. However, there was no significant association between cardiotoxicity and the number of chemotherapy cycles, total cumulative dose of doxorubicin, or history of radiation. Furthermore, patients with cardiotoxicity had a higher risk of mortality. The overall survival of the patients was 18 months. Conclusion: Doxorubicin-associated cardiotoxicity is a concern for patients with sarcoma. Female patients and patients with a higher ECOG performance status are at an increased risk of developing cardiotoxicity. Careful monitoring and risk assessment are crucial for mitigating the adverse effects of doxorubicin treatment in patients with sarcoma. Future studies are warranted to validate these findings and explore preventive strategies for doxorubicin-induced cardiotoxicity in patients with sarcoma.
- Open Access
Antibiotic Exposure Concurrently with Anti-PD1 Blockade Therapy Reduces Overall Survival in Patients with Child–Pugh Class A Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide with a poor prognosis. Treatment with immune checkpoint inhibitors (ICIs) has improved overall survival in patients with HCC. However, not all patients benefit from the treatment. In this study, 59 patients with HCC were enrolled from two medical centers in Saudi Arabia, with 34% using antibiotics concurrently with their Nivolumab (anti-PD1 blockade). The impact of antibiotic use on the clinical outcomes of patients with HCC undergoing treatment with anti-PD1 blockade was examined. The patients’ overall survival (OS) was 5 months (95% CI: 3.2, 6.7) compared to 10 months (95% CI: 0, 22.2) (p = 0.08). Notably, patients with Child–Pugh A cirrhosis receiving anti-PD1 blockade treatment without concurrent antibiotic use showed a significantly longer median OS reaching 22 months (95% CI: 6.5, 37.4) compared to those who were given antibiotics with a median OS of 6 months (95% CI: 2.7, 9.2) (p = 0.02). This difference in overall survival was particularly found in Child–Pugh class A patients receiving anti-PD1 blockade. These findings suggest that antibiotic use may negatively affect survival outcomes in HCC patients undergoing anti-PD1 blockade, potentially due to antibiotic-induced alterations to the gut microbiome impacting the anti-PD1 blockade response. This study suggests the need for careful consideration when prescribing antibiotics to patients with HCC receiving anti-PD1 blockade.
Open AccessAntibiotic Exposure Concurrently with Anti-PD1 Blockade Therapy Reduces Overall Survival in Patients with Child–Pugh Class A Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide with a poor prognosis. Treatment with immune checkpoint inhibitors (ICIs) has improved overall survival in patients with HCC. However, not all patients benefit from the treatment. In this study, 59 patients with HCC were enrolled from two medical centers in Saudi Arabia, with 34% using antibiotics concurrently with their Nivolumab (anti-PD1 blockade). The impact of antibiotic use on the clinical outcomes of patients with HCC undergoing treatment with anti-PD1 blockade was examined. The patients’ overall survival (OS) was 5 months (95% CI: 3.2, 6.7) compared to 10 months (95% CI: 0, 22.2) (p = 0.08). Notably, patients with Child–Pugh A cirrhosis receiving anti-PD1 blockade treatment without concurrent antibiotic use showed a significantly longer median OS reaching 22 months (95% CI: 6.5, 37.4) compared to those who were given antibiotics with a median OS of 6 months (95% CI: 2.7, 9.2) (p = 0.02). This difference in overall survival was particularly found in Child–Pugh class A patients receiving anti-PD1 blockade. These findings suggest that antibiotic use may negatively affect survival outcomes in HCC patients undergoing anti-PD1 blockade, potentially due to antibiotic-induced alterations to the gut microbiome impacting the anti-PD1 blockade response. This study suggests the need for careful consideration when prescribing antibiotics to patients with HCC receiving anti-PD1 blockade.
- Open Access
- 1 December 2021
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 20 (4) , 334-341
Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer
- 1 December 2021
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 20 (4) , 334-341
Open AccessPhase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer